{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:52:12Z","timestamp":1790657532910,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1053\/j.seminhematol.2024.06.002","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:10:59Z","timestamp":1718410259000},"page":"229-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of response adapted therapy in the era of novel agents"],"prefix":"10.1053","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4128-2537","authenticated-orcid":false,"given":"Joseph G.","family":"Schroers-Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.002_bib0001","doi-asserted-by":"crossref","first-page":"322","DOI":"10.6004\/jnccn.2022.0021","article-title":"NCCN Guidelines\u00ae insights: Hodgkin lymphoma, version 2.2022: featured updates to the NCCN Guidelines","volume":"20","author":"Hoppe","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.06.002_bib0002","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood.V73.1.47.47","article-title":"Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC lymphoma group controlled clinical trials: 1964-1987","volume":"73","author":"Tubiana","year":"1989","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.06.002_bib0003","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1200\/JCO.1997.15.6.2275","article-title":"Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease","volume":"15","author":"Loeffler","year":"1997","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.06.002_bib0004","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the first international workshop on interim-PET scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.06.002_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.23.01177","article-title":"Long-term follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma trial","volume":"42","author":"Luminari","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10114","key":"10.1053\/j.seminhematol.2024.06.002_bib0006","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.06.002_bib0007","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.06.002_bib0008","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.06.002_bib0009","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.06.002_bib0010","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"New Engl J Med"},{"issue":"31","key":"10.1053\/j.seminhematol.2024.06.002_bib0011","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography\u2013guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.06.002_bib0012","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.002_bib0013","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"New Engl J Med"},{"issue":"17)","key":"10.1053\/j.seminhematol.2024.06.002_bib0014","doi-asserted-by":"crossref","first-page":"Suppl LBA4","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab (N)-AVD versus brentuximab vedotin (BV)-AVD in advanced stage (AS) classic hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.06.002_bib0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00277-021-04460-9","article-title":"Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial","volume":"100","author":"Russell","year":"2021","journal-title":"Annals of Hematology"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.06.002_bib0016","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(21)00101-0","article-title":"PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Kreissl","year":"2021","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.06.002_bib0017","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1200\/JCO.21.01777","article-title":"Positron emission tomography\u2013driven strategy in advanced Hodgkin lymphoma: prolonged follow-up of the AHL2011 phase III lymphoma study association study","volume":"40","author":"Casasnovas","year":"2022","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.06.002_bib0018","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.06.002_bib0019","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.06.002_bib0020","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.06.002_bib0021","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/bloodadvances.2022008116","article-title":"Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma","volume":"7","author":"Allen","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.06.002_bib0022","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41375-021-01386-z","article-title":"Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group","volume":"36","author":"Damaschin","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.06.002_bib0023","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","article-title":"Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin study group","volume":"18","author":"Eichenauer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2024.06.002_bib0024","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1182\/blood-2023-188720","article-title":"Comprehensive analysis of treatment related morbidity and progression-free survival in the GHSG phase III HD21 trial","volume":"142","author":"Borchmann","year":"2023","journal-title":"Blood"},{"issue":"17_suppl","key":"10.1053\/j.seminhematol.2024.06.002_bib0025","doi-asserted-by":"crossref","first-page":"LBA7000","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA7000","article-title":"Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study","volume":"42","author":"Borchmann","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.06.002_bib0026","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1200\/JCO.23.01386","article-title":"Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma","volume":"42","author":"Neppelenbroek","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.06.002_bib0027","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/bloodadvances.2022008420","article-title":"Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma","volume":"7","author":"Abramson","year":"2023","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.06.002_bib0028","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1182\/blood-2022-159258","article-title":"Frontline PET-directed therapy with brentuximab vedotin plus AVD followed by nivolumab consolidation in patients with limited stage Hodgkin lymphoma","volume":"140","author":"Park","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.06.002_bib0029","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab vedotin Plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial","volume":"41","author":"Fornecker","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.06.002_bib0030","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.06.002_bib0031","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable hodgkin lymphoma: final analysis of the randomized German Hodgkin study group phase II NIVAHL Trial","volume":"41","author":"Br\u00f6ckelmann","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.002_bib0032","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.06.002_bib0033","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non\u2013cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.06.002_bib0034","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1\/2 study","volume":"8","author":"Lynch","year":"2021","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.06.002_bib0035","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.06.002_bib0036","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.06.002_bib0037","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1\u2013based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.06.002_bib0038","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Canc Res"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.06.002_bib0039","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1158\/1078-0432.CCR-14-3128","article-title":"CCR 20th anniversary commentary: immune-related response criteria\u2014capturing clinical activity in immuno-oncology","volume":"21","author":"Hoos","year":"2015","journal-title":"Clin Canc Res"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.06.002_bib0040","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.06.002_bib0041","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/hon.3137","article-title":"Advances in positron emission tomography and radiomics","volume":"41","author":"Barrington","year":"2023","journal-title":"Hematol Oncol"},{"issue":"1127","key":"10.1053\/j.seminhematol.2024.06.002_bib0042","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210448","article-title":"Total tumor burden in lymphoma\u2013an evolving strong prognostic parameter","volume":"94","author":"Meignan","year":"2021","journal-title":"British J Radiol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.06.002_bib0043","doi-asserted-by":"crossref","first-page":"23195","DOI":"10.1038\/s41598-021-02734-w","article-title":"Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin's lymphoma","volume":"11","author":"Pinochet","year":"2021","journal-title":"Sci Rep"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.06.002_bib0044","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.3324\/haematol.2021.280004","article-title":"High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline","volume":"107","author":"Rossi","year":"2022","journal-title":"Haematological"},{"key":"10.1053\/j.seminhematol.2024.06.002_bib0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/hon.3163_56","article-title":"Baseline SUV and early response, but not MTV, are associated with outcome in relapsed\/refractory Hodgkin lymphoma patients treated with nivolumab in the CheckMate 205 trial","volume":"41","author":"Barrington","year":"2023","journal-title":"Hematol Oncol"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.06.002_bib0046","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","article-title":"Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.002_bib0047","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/hon.3025","article-title":"Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: a radio-genomic study","volume":"40","author":"Durmo","year":"2022","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2024.06.002_bib0048","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood-2021-147177","article-title":"Total metabolic tumor volume and tumor dissemination are independent prognostic factors in advanced Hodgkin lymphoma","volume":"138","author":"Kanoun","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.06.002_bib0049","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/bloodadvances.2021004467","article-title":"Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients","volume":"5","author":"Eertink","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.06.002_bib0050","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.06.002_bib0051","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/diagnostics12020417","article-title":"Deep learning approach to automatize TMTV calculations regardless of segmentation methodology for major FDG-avid lymphomas","volume":"12","author":"Revailler","year":"2022","journal-title":"Diagnostics"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.06.002_bib0052","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.06.002_bib0053","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.medj.2021.09.002","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med"},{"issue":"7996","key":"10.1053\/j.seminhematol.2024.06.002_bib0054","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.06.002_bib0055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3324\/haematol.2019.237719","article-title":"Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study","volume":"106","author":"Camus","year":"2020","journal-title":"Haematological"},{"issue":"28","key":"10.1053\/j.seminhematol.2024.06.002_bib0056","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.06.002_bib0057","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjh.19162","article-title":"Baseline circulating tumour DNA and interim PET predict response in relapsed\/refractory classical Hodgkin lymphoma","volume":"204","author":"Calabretta","year":"2024","journal-title":"Br J Haematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T13:04:52Z","timestamp":1726837492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0037196324000726"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.06.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of response adapted therapy in the era of novel agents","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}